. 2021 Dec 16;12:797298. doi: 10.3389/fphar.2021.797298

TABLE 3.

Comprehensive information about the effects of myricetin in animal models Parkinson’s disease.

Pharmacological effect	Object	Drug administration	Possible mechanisms	References
Reverse 6-OHDA-induced decrease in dopamine contents in the striatum	Rat	*0.5 mg/ml	Increase tyrosine hydroxylase expression and reduce iron-staining cells in the substantia nigra	Ma et al. (2007)
		*lateral cerebral ventricle injection
		*7 days
Suppress rotenone-induced gait disturbance, muscular dys-coordination, memory impairment, dopaminergic neuronal degeneration, and dopamine reduction	Drosophila	*314 mM	*Reduce TBARS levels and Bax expression	Dhanraj et al. (2018)
		*3 h before rotenone exposure	*Increase GSH levels and Bcl-2 expression
		*7 days	—
Attenuate MPP⁺-induced cell loss and nuclear condensation	MES23.5 cells	50 μM Co-treatment	*Restore mitochondrial transmembrane potential	Zhang et al. (2011)
Attenuate MPP⁺-induced cell loss and nuclear condensation	MES23.5 cells	50 μM Co-treatment	*Suppress reactive oxygen species production	Zhang et al. (2011)
Prevent rotenone-induced cell loss	SH-SY5Y cells	*50 μM	*Suppress DNA fragmentation, lipid peroxidation, and the production of hydrogen peroxide and superoxide anion	Molina-Jiménez et al. (2004)
Prevent rotenone-induced cell loss	SH-SY5Y cells	*30 min before rotenone treatment		Molina-Jiménez et al. (2004)
Alleviate rotenone-induced decreases in cell viability	MES23.5 cells	*1 μM	*Suppress reactive oxygen species production	Deng et al. (2021)
		*24 h of pretreatment	*Restore mitochondrial transmembrane potential
		—	*Reduce hepcidin gene transcription
		—	*Increase ferroportin 1 expression
Suppress the aggregation of the mutant α-synuclein (S87A) protein	Cos-7 cells	*10 μM	Activate the ubiquitin-proteasome pathway	Joshi et al. (2019)
	Cos-7 cells	*48 h	Activate the ubiquitin-proteasome pathway	Joshi et al. (2019)